SoftOx Solutions raised NOK 50 million through its private placement after the
stock exchange closing on Wednesday, December 16th. The interest for the capital
increase was high, and more than 100 percent oversubscribed.

- This demonstrates that we have confidence in the market, that we are on the
right track and it will give us the power we need for our future plans. We are
experiencing exciting times at SoftOx, both in product development and
commercialization in Norway and internationally, says CEO Geir Almås of SoftOx
Solutions.

This capital increase will contribute to further research, including the ongoing
lung studies at the University of Copenhagen, where the company's goal is to
start testing in humans early 2021.

The company will now also be able to intensify its activities related to the
investment in its alcohol-free and skin-friendly hand sanitizers AntiVir and
SafeDes towards several large markets in Europe and Asia.

Practical information regarding the capital Increase					     

The private placement is divided into two tranches:  tranche 1 consists of
500,000 shares and tranche 2 with 409 090 shares. It is also proposed to offer a
repair issue (subject to approval by the company's General Assembly which is
tentatively scheduled to meet on January 4th, 2021) directed at those
shareholders who did not subscribe for shares on December 16th in the private
placement. Up to NOK 10 million will be raised in the repair issue at the same
subscription price (NOK 55.00). 

The purpose of the proposed repair issue is to give shareholders who did not get
the chance to participate in the private placement the opportunity to subscribe
to the same terms as in the private placement - and thus in part "repair" the
dilution of ownership. 


Oslo, December 18th  2020

Contact:

Geir Almås, CEO of SoftOx Solutions AS
Mail: geir.almaas@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS								            
SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth)
is a Norwegian MedTech company based in Oslo with the aim of helping to combat
major threats to human health, namely the emergence of antimicrobial resistance
(AMR), biofilm infections in chronic wounds and the spread of viruses. For more
information on SoftOx, visit www.soft-ox.com